Literature DB >> 10321445

Changes in antihypertensive therapy--the role of adverse effects and compliance.

R Düsing1, B Weisser, T Mengden, H Vetter.   

Abstract

In a German multicentre study (1603 patients, 320 private practices), adverse effects and patient compliance during antihypertensive therapy were investigated using standardized questionnaires for both patient and physician. Patients with a change in antihypertensive therapy during the last six months were included in this study. The single most important reason for the change in therapy was inadequate blood pressure control (48.4%), followed by adverse effects (30.1%), patient dissatisfaction (20.0%), non-compliance (16.8%) and cost (4.9%). The most frequent adverse effects noted by the doctors were cough (51.9%), oedema (36.9%), flush (36.6) and dizziness (27.8%). In comparing the answers of the physicians and patients, it becomes obvious that compliance may be overestimated by the doctors (good: 41.7%; medium: 57.3%; bad: 1.0%), since only 32.3% of the patients stated that they never missed a dose, 54.8% were occasionally non-compliant and 12.9% admitted missing a dose frequently. The predominant reasons for non-compliance (assessed by the patients) were forgetfulness (40.4%), followed by adverse effects (9.6%) and irregular lifestyle (6.5%). Thus, lack of effectiveness and adverse effects/patient dissatisfaction/non-compliance contributed roughly equally to the decision to change therapy. In addition, forgetfulness was shown to be an important contributor to suboptimal compliance. Lastly, physicians may still underestimate the extent of non-compliance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10321445     DOI: 10.1080/080370598437187

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  21 in total

Review 1.  Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence?

Authors:  K A Payne; S Esmonde-White
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

Review 2.  Adverse events, compliance, and changes in therapy.

Authors:  R Düsing
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 3.  Pharmacoeconomics of hypertension management: the place of combination therapy.

Authors:  E Ambrosioni
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 4.  Risk: benefit of treating high blood pressure in older adults.

Authors:  Omar Mukhtar; Stephen H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

5.  Continuous and interval training programs using deep water running improves functional fitness and blood pressure in the older adults.

Authors:  Thaís Reichert; Ana Carolina Kanitz; Rodrigo Sudatti Delevatti; Natália Carvalho Bagatini; Bruna Machado Barroso; Luiz Fernando Martins Kruel
Journal:  Age (Dordr)       Date:  2016-02-03

6.  A Case for a Holistic Approach to the Improvement of Compliance among Hypertensive Patients: A Hospital Review.

Authors:  M Gossell-Williams; J Williams-Johnson; E W Williams; P Levy
Journal:  West Indian Med J       Date:  2014-06-12       Impact factor: 0.171

7.  Postmarketing surveillance study of benazepril in chinese patients with hypertension: An open-label, experimental, epidemiologic study.

Authors:  Jun Lu; Liming Lee; Weihua Cao; Siyan Zhan; Guoying Zhu; Liqiang Dai; Yonghua Hu
Journal:  Curr Ther Res Clin Exp       Date:  2004-05

Review 8.  Effect of antihypertensive agents on quality of life in the elderly.

Authors:  Roberto Fogari; Annalisa Zoppi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 9.  Optimizing blood pressure control through the use of fixed combinations.

Authors:  Rainer Düsing
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

Review 10.  Optimizing medication adherence in older persons with hypertension.

Authors:  William J Elliott
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.